Navigation Links
Visionsense Announces Food and Drug Administration (FDA) 510(k) Clearance for VSII - Visionsense Stereoscopic Vision System
Date:3/18/2008

ORANGEBURG, N.Y., March 18 /PRNewswire/ -- Visionsense Corp. announces FDA 510(k) Clearance of the new VSII -- Visionsense Stereoscopic Vision System. The system is based on a miniature 3.4 mm distal ("chip-on-a-stick") stereoscopic 3D camera targeting Minimal Invasive laparoscopic and endoscopic Surgery (MIS).

Visionsense's stereoscopic 3D camera enables and enhances MIS surgical procedures that are under served by traditional 2D visualization, in markets such as: Spine, Neurosurgery, Orthopedics, Endoscopy, General Surgery, GYN, Robotics, and others.

The company has licensed the technology to various strategic marketing partners, expecting launches later this year.

About Visionsense Corp.

Visionsense exclusively licenses its technology, application or segment specific, to strategic partners, benefiting a unique competitive advantage. The Company develops and manufactures customized Miniature Stereoscopic 3D cameras/sensors that enable surgeons to see "natural" Stereovision, thus enhancing image understanding and hand-eye coordination. These re-useable or disposable cameras are distally assembled on the tip of a flexible / rigid scope or instrument. The technology further assists the surgeon by providing advanced software features, such as image fusion (combining stereovision with MRI, CT or ultrasound for real-time "see-through-tissue") and 3D measurements.

For more information please call:

Joe Rollero

Executive Vice President

Business Development

Visionsense Corp.

40 Ramland Road, Suite 202

Orangeburg, NY 10962

Phone: 845-680-0233

Email: jrollero@visionsense.com

http://www.visionsense.com


'/>"/>
SOURCE Visionsense Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
3. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
4. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
5. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
6. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
7. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
8. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
9. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
10. Angiotech announces additional diameters of sutures to further expand its Quill(TM) SRS PDO product line
11. CNS Response Announces Fiscal Third Quarter 2007 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/18/2014)... 2014 PDL BioPharma, Inc. (PDL) (NASDAQ: ... the acquisition of Durata Therapeutics, Inc. by Actavis, PDL ... termination of PDL,s credit agreement with Durata, which included ... million, accrued interest, and prepayment and change of control ... financing transaction with Durata in which PDL agreed to ...
(Date:11/17/2014)... The new METTLER TOLEDO White Paper ... challenges of becoming the first calibration laboratory in ... weights in the microgram range. National Metrology Institutes ... scientists involved in nanotechnology applications will benefit from ... calibration of weights in the range of 0.05 ...
(Date:11/15/2014)... (PRWEB) November 13, 2014 Collaborative Consulting, ... they were named one of the Boston Globe’s “Top ... Medium Sized Businesses in Massachusetts to receive the honor. ... employers who take care of their most valuable resource: ... are presented annually, and are based on an array ...
(Date:11/15/2014)... November 14, 2014 CannLabs, ... proprietary, cloud-based analytics, and scientific testing methodologies relating ... third quarter ended September 30, 2014, and provided ... ,     CannLabs – Nevada, Inc. granted ... Nevada. ,     CannLabs – Connecticut, Inc. opened ...
Breaking Biology Technology:PDL BioPharma Announces Successful Conclusion of Debt Financing Agreement with Durata Therapeutics 2New White Paper on Microgram Weights Describes How to Achieve Traceable Measurement Down to 0.05 Milligrams 2Collaborative Consulting Honored with Boston Globe Top Places to Work 2014 2CannLabs Announces Third Quarter 2014 Results. 2CannLabs Announces Third Quarter 2014 Results. 3CannLabs Announces Third Quarter 2014 Results. 4CannLabs Announces Third Quarter 2014 Results. 5
... Oncology Adjuvant Trial 9735 at 2007 San, ... Improved Overall Survival Versus ... Results presented at the,30th annual San Antonio ... early stage breast cancer who have had surgery, ...
... FDA-defined Valvulopathy Permitted to Enroll in 2nd and ... Screening Requirement Eliminated, SAN DIEGO, Dec. 13 ... announced the initiation of patient screening in,the second ... efficacy and,safety of its lead drug candidate, lorcaserin ...
... SAN DIEGO, Dec. 13 BioMed Realty Trust, Inc.,(NYSE: ... I. Gilchrist to its,board of directors, increasing the board ... in the real estate industry, with a breadth of,ability ... large-scale commercial real estate projects. We believe that,Rick,s contributions ...
Cached Biology Technology:Taxotere(R)-Based Chemotherapy Significantly Improved Overall Survival Compared With Standard Anthracycline-Based Chemotherapy in Early Stage Breast Cancer 2Taxotere(R)-Based Chemotherapy Significantly Improved Overall Survival Compared With Standard Anthracycline-Based Chemotherapy in Early Stage Breast Cancer 3Taxotere(R)-Based Chemotherapy Significantly Improved Overall Survival Compared With Standard Anthracycline-Based Chemotherapy in Early Stage Breast Cancer 4Taxotere(R)-Based Chemotherapy Significantly Improved Overall Survival Compared With Standard Anthracycline-Based Chemotherapy in Early Stage Breast Cancer 5Arena Pharmaceuticals Initiates Second and Third Pivotal Trials Evaluating Lorcaserin for the Treatment of Obesity 2Arena Pharmaceuticals Initiates Second and Third Pivotal Trials Evaluating Lorcaserin for the Treatment of Obesity 3Arena Pharmaceuticals Initiates Second and Third Pivotal Trials Evaluating Lorcaserin for the Treatment of Obesity 4Arena Pharmaceuticals Initiates Second and Third Pivotal Trials Evaluating Lorcaserin for the Treatment of Obesity 5Arena Pharmaceuticals Initiates Second and Third Pivotal Trials Evaluating Lorcaserin for the Treatment of Obesity 6BioMed Realty Trust Appoints Executive Officer of the Irvine Company to Its Board 2BioMed Realty Trust Appoints Executive Officer of the Irvine Company to Its Board 3
(Date:11/4/2014)... 2014   Neurotechnology , a provider of ... latest version of its fingerprint matching algorithm has ... evaluation organized by NIST. The MINEX test ... INCITS 378 fingerprint standard template format. MINEX compliance ... in the United States ...
(Date:11/3/2014)... 3, 2014  NeuroSigma ® , Inc. (NeuroSigma), ... company focused on commercialization of its non-invasive ... treatment of neurological and neuropsychiatric disorders, announced today ... issued a Notice of Allowance for Mexican Patent ... by NeuroSigma and the Regents of the University ...
(Date:11/2/2014)... LA (2 November 2014)—In support of a bold quest ... & Melinda Gates Foundation today announced an award of ... Vaccine Initiative (MVI) in building new vaccines that will ... realize the "accelerating to zero" agenda. Such vaccines would ... could be called an "immunological bed net." , ...
Breaking Biology News(10 mins):Neurotechnology Places Second in Ongoing MINEX Ranking for Fingerprint Matching Algorithms 2Neurotechnology Places Second in Ongoing MINEX Ranking for Fingerprint Matching Algorithms 3NeuroSigma Receives Notice of Allowance from the Mexican Institute of Industrial Property Covering Subcutaneous Trigeminal Nerve Stimulation (sTNS) 2NeuroSigma Receives Notice of Allowance from the Mexican Institute of Industrial Property Covering Subcutaneous Trigeminal Nerve Stimulation (sTNS) 3New malaria vaccines to prevent infection and block transmission get a shot in the arm 2New malaria vaccines to prevent infection and block transmission get a shot in the arm 3New malaria vaccines to prevent infection and block transmission get a shot in the arm 4
... Scientists at Stanford University have developed a new laser ... unharmed. The new, non-invasive treatment is described in a ... the Proceedings of the National Academy of Sciences (PNAS). ... how to cure cancer without harming normal body tissue," ...
... from sensory neurons using a code more complicated than ... National Autonomous University of Mexico and Cold Spring Harbor ... when it touches the skin, scientists found that changes ... sensory signal is interpreted. , Howard Hughes Medical Institute ...
... looking deep under water for clues on how to ... Some of the stresses inherent with travel and life ... example - are not easily remedied with traditional plant ... Distinguished Professor of Botany, and Dr.Amy Grunden, assistant professor ...
Cached Biology News:Scientists develop nanotech-laser treatment that kills cancer cells without harming healthy tissue 2Scientists develop nanotech-laser treatment that kills cancer cells without harming healthy tissue 3Scientists develop nanotech-laser treatment that kills cancer cells without harming healthy tissue 4Cracking the perception code 2Cracking the perception code 3NC State researchers redesign life for Mars and beyond 2
... polyacrylamide gel electrophoresis (2D-PAGE) with biological mass ... technology platform for proteomic analysis. 2D-PAGE gels ... limited only in the dynamic range and ... Quantitative image based analysis of separated proteins ...
... The BV-10 offers precision ... 0.1 and 50m. The unique ... vibration free for greater control ... can be accomplished very rapidly ...
... EC570-90 is a compact, lightweight, high current power ... or 2500 milliamps. It is an excellent choice ... gels. It is also ideal for all types ... be set to automatically end a run and ...
... is a highly purified preparation qualified to ... vectors. The preparation is functionally tested for ... of detectable contaminating proteases. Prepared from human ... tests to be negative for HBsAg and ...
Biology Products: